An interdisciplinary analysis of the development of drugs for Alzheimer disease. Alongside and intertwined with the theme of drug development is thorough scrutiny of the concepts of Alzheimer disease and dementia from a wealth of viewpoints.(JAMA)
About the Author
Jesse F. Ballenger, Ph.D., is an assistant professor in the Science, Technology, and Society Program at Pennsylvania State University. Peter J. Whitehouse, M.D., Ph.D., is the director of integrative studies at Case Western Reserve University. Constantine G. Lyketsos, M.D., M.H.S., is the Elizabeth Plank Althouse Professor in Alzheimer's Disease Research at Johns Hopkins, where he is chair of the Department of Psychiatry at the Bayview Medical Center, vice-chair of the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins Hospital, co-director of the Division of Geriatric Psychiatry and Neuropsychiatry, and director of the Memory and Alzheimer's Treatment Center. Peter V. Rabins, M.D., M.P.H., is the vice-chair for Faculty Academic Affairs at the Johns Hopkins University, where he is co-director of the Division of Geriatric Psychiatry and Neuropsychiatry and a professor of psychiatry and behavioral sciences. Jason H. T. Karlawish, M.D., is an associate professor of medicine and medical ethics at the University of Pennsylvania.